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CASE REPORT
Severe eosinophilic asthma 
and aspirin-exacerbated respiratory disease 
associated to eosinophilic gastroenteritis 
treated with mepolizumab: a case report
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Abstract 
Background: Mepolizumab (MEP) is the first anti Interleukin (IL)-5 add-on therapy approved for the treatment of 
severe refractory eosinophilic asthma.
Case presentation: We describe here the case of a 49 years-old woman with Aspirin-exacerbated respiratory disease 
(AERD), chronic rhinosinusitis, nasal polyposis and eosinophilic gastroenteritis successfully treated with MEP. Several 
laboratory and clinical items improved during therapy; moreover MEP showed to be useful as steroid sparing agent.
Conclusions: This case supports that the use of mepolizumab can be effective also in other eosinophilic conditions 
different from asthma and this opens to new therapeutic perspectives.
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Background
Aspirin-exacerbated respiratory disease (AERD) is 
characterized by chronic eosinophilic nasal polyps, 
asthma, and airway reactions upon cyclooxygenase 
(COX) 1 inhibition and affects 1.9% of the European 
population [1]. Eosinophilic gastroenteritis (EGE) is a rare 
primary eosinophilic gastrointestinal disorder (EGID), 
of unknown etiology, characterized by the presence of 
an intense eosinophilic infiltrate on histopathological 
examination of the gastric and intestinal mucosa.
The overall prevalence of eosinophilic enteritis 
is estimated at 5.1/100,000 persons, with peaks of 
incidence between the third and fifth decade of life 
[2]. Hypersensitivity response seems to play a key 
role in pathogenesis of EGE and several patients show 
association with other conditions such as seasonal 
allergies, food allergy, asthma, and eczema.
Mepolizumab (MEP) is the first anti Interleukin 
(IL)-5 add-on therapy approved for the treatment of 
severe refractory eosinophilic asthma [3]. Eosinophil 
differentiation, survival, and activation are preferentially 
regulated by IL-5, a cytokine that binds to the IL-5 
receptor (IL-5R), which is located on the surface of 
eosinophils or basophils and plays a critical role in the 
pathogenesis and severity of asthma [4]. Recently, one 
case report of a successfully treatment of both severe 
asthma and EGE with mepolizumab plus omalizumab 
(anti-immunoglobulin E monoclonal antibody) has been 
reported [5].
We describe here the case of a woman suffering from 
severe eosinophilic asthma and AERD associated to EGE 
successfully treated with MEP.
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Case presentation
A 49  years-old woman with ten-year recurrent non-
bloody watery diarrhea and abdominal pain came to our 
observation in 2015. No family history of gastrointestinal 
disorders was detected. A full ileocolonscopy performed 
5  years before (no biopsies collected) was normal, 
leading to a diagnosis of an irritable bowel syndrome, 
so managed with symptomatic drugs without significant 
clinical benefit. She had also an history of repeated 
endoscopic sinus surgery (ESS) because of polyps’ 
recurrence, aspirin-exacerbated respiratory disease and 
severe eosinophilic asthma with frequent exacerbations, 
requiring short courses of oral corticosteroids. Over 
the years, it appeared that oral steroids induced also 
a complete relief of gastrointestinal symptoms, with a 
relapse at withdrawal. Therefore, the patient had repeated 
steroids exposure, developing dependence and several 
side-effects.
At admission to our department, she complained 
watery diarrhea (5–6 bowel movements/day) preceded 
by abdominal pain. Her vital signs were: SpO2 95% 
(room air), Temperature 35.8  °C, Heart Rate 100  bpm, 
Respiratory Rate 18/m, Blood Pressure 108/60 mmHg.
Physical examination was significant only for mild 
tenderness in the mesogastric area with intact bowel 
sounds. No organomegaly was found. Visual analog 
scale (VAS) score for abdominal pain was moderate/
severe (60). Besides elevated peripheral blood eosinophil 
(0.38 × 109/L) laboratory tests were unremarkable. Stool 
examinations were negative for parasitic, bacteria and 
clostridium difficile infections. Pulmonary functional 
tests revealed a Forced Expiratory Volume in the first 
second (FEV1) of 63% (of predicted value), Asthma 
Control Test (ACT) score was 13, Sino-Nasal Outcome 
Test (SNOT-22) was 93, Lund–Mackay (LM) score was 
20. Baseline mean OCS dose was 15  mg of prednisone 
per day. Four OCS requiring asthmatic exacerbations 
occurred during the previous year.
An ileocolonscopy revealed a normal aspect of the 
mucosa of each explored segment, except for a small 
polyp (2 mm) in the rectum, that was removed. Biopsies 
collected from apparently normal mucosa showed instead 
an important linfoplasmacellular and granulocytic 
infiltrate in the lamina propria with a predominance of 
eosinophils (Fig. 1a, b).
Moreover, no significant findings emerged from 
gastroscopy, but biopsy specimens, collected in antrum, 
showed as well as the linfomonocytic and eosinophil 
granulocytic infiltrate disrupting the glandular structures 
(Fig. 1c).
According to the immunopathogenetic mechanisms 
of the diseases and in order to spare oral steroids, in 
2017, we started treatment with subcutaneous MEP at 
the standard dose of 100  mg every 4  weeks, using the 
severe eosinophilic asthma schedule.
As expected, blood eosinophil count was reduced 
after the first administration, and became lower 
and lower during the next 48  weeks (30 cells/mm3). 
After 3  months, patient experienced a significant 
improvement of sinusitic, respiratory as well as 
gastrointestinal symptoms. FEV1 and SNOT-22 
were evaluated at 6 and 12  month, showing a global 
improvement (75% and 95%; 51 and 21 respectively). 
ACT raised to 23. LM score reduced to 8 at month 
12. VAS score for abdominal pain reduced to 20 after 
3  months so gradually all oral corticosteroids were 
successfully reduced by patient. After 6 months, patient 
was in steroid-free clinical remission with a stool 
frequency of 1–2 movements/day of normal feces (type 
3 according to the Bristol stool chart) and a complete 
resolution of abdominal pain. BMI (Body Mass Index) 
reduced from 28 to 23 and none asthma exacerbation 
occurred during the first year of treatment and until the 
last follow-up evaluation (24 months) [6].
Endoscopies were repeated in order to obtain new 
biopsy specimens, showing a remission of the disease in 
term of eosinophilic inflammation, glands where normal 
and neither reactive hyperchromatic changes, nor mucin 
depletion can be appreciated (Fig. 1d–f).
Basophils activation was evaluated after 12 months of 
MEP, using the surface molecules CD203c, CD63 and 
CD125, showing a reduction of activation percentages. 
Results are shown in Fig.  2a, b [7]. Serum IL-5 levels 
(R&D Systems; sensitivity: 0.29 pg/ml) were measured at 
baseline and after 3, 6 and 12  months of treatment and 
are shown in Fig. 2. Serum IL-5 was non-quantifiable at 
baseline and showed an increase with peak on 6 months 
as expected and previously demonstrated by Pouliquen 
et al. in 2015 (Fig. 2c) [8].
Discussion
The case of this woman affected by AERD, chronic 
rhinosinusitis, nasal polyposis and EGE successfully 
treated with MEP supports recent literature data that 
show how new biological agents may be useful in 
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eosinophilic conditions other than asthma. Several 
laboratory and clinical items improved during therapy; 
moreover MEP showed to be useful as steroid sparing 
agent. As for AERD, interestingly, at the moment, after 
2 years treatment, symptom scores for anosmia (Question 
21 from the SNOT-22) and nasal congestion (Question 
22 from the SNOT-22) are significantly decreased. Also 
the response of nasal symptoms and the CT findings 
obtained with MEP in this patient are remarkable and 
confirm more recent literature data [9].
Conclusion
This case suggests that MEP could be effective in the 
treatment of eosinophilic disorders other than asthma, 
i.e. EGE and AERD. Obviously long term observations 
and further investigations are needed to define better 
the therapeutic management of these diseases, however 
the description of different cases with different 
comorbidities could help to define different aspects of 
therapy in terms of schedule, drug dosage, duration and 
so on.
Fig. 1 a (Hematoxylin and Eosin, ×10): in this picture an important linfoplasmacellular ad granulocytic infiltrate is appreciable in the lamina propria 
with a predominance of eosinophilis, with an infiltrating pattern sometimes disrupting glandular integrity. b (Hematoxylin and Eosin, ×20): a 
particular of the previous where eosinophils granulocytes surround and infiltrate the glands. As a consequence, glandular structures are depleted of 
their goblet cells and show reactive hyperchromatic nuclei. c (Hematoxylin and Eosin, ×40): this is an atrophic field where the linfomonocytic and 
eosinophil granulocitic infiltrate disrupt the glandular structures evocating atrophy and reactive changes. d (Hematoxylin and Eosin, ×10): this is 
a picture of the same patient after therapy. You can appreciate the lamina propria devoid of inflammatory infiltrate. The glands are well separated, 
normoconformed and with a goblet component normorapresented. Just in a focal small field there’s a linfomonocytic infiltrate, where no one can 
appreciate eosinophilic component. e (Hematoxylin and Eosin, ×20): a particular of the previous, where glands are normal and neither a significant 
eosinophilic infiltrate, nor reactive hyperchromatic changes, nor mucin depletion can be appreciated. f (Hematoxylin and Eosin, ×20): as the 
previous one, glandular mucosal component is conserved and just a focal eosinophilic infiltrate in three different glands is present, but without any 
specific feature
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